Lindenwold Advisors INC Invests $239,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Lindenwold Advisors INC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,000 shares of the biopharmaceutical company's stock, valued at approximately $239,000.

A number of other institutional investors have also made changes to their positions in HALO. GSA Capital Partners LLP acquired a new position in Halozyme Therapeutics during the third quarter worth $217,000. CIBC Asset Management Inc acquired a new position in Halozyme Therapeutics during the third quarter worth $211,000. Natixis Advisors LLC increased its holdings in Halozyme Therapeutics by 86.7% during the third quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company's stock worth $6,958,000 after buying an additional 56,461 shares during the last quarter. TrinityPoint Wealth LLC acquired a new position in Halozyme Therapeutics during the third quarter worth $214,000. Finally, Quest Partners LLC increased its holdings in Halozyme Therapeutics by 1,386.0% during the third quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company's stock worth $561,000 after buying an additional 9,134 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Benchmark restated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $62.78.

Remove Ads

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $0.84 during trading on Friday, hitting $65.16. The company had a trading volume of 4,001,023 shares, compared to its average volume of 1,329,696. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a market capitalization of $8.05 billion, a P/E ratio of 19.00, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The stock's 50-day moving average price is $58.20 and its 200 day moving average price is $54.66. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock worth $1,754,451 over the last three months. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.